Nutrition, mobility predict early death in elderly cancer patients

April 17, 2012
Nutrition, mobility predict early death in elderly cancer patients
Low nutritional assessment scores, poor mobility, and advanced disease predict early death after chemotherapy initiation among elderly patients with cancer, according to a study published online April 16 in the Journal of Clinical Oncology.

(HealthDay) -- Low nutritional assessment scores, poor mobility, and advanced disease predict early death after chemotherapy initiation among elderly patients with cancer, according to a study published online April 16 in the Journal of Clinical Oncology.

To investigate factors that predict death within six months of chemotherapy initiation, Pierre Soubeyran, M.D., Ph.D., of the Bordeaux Segalen University in France, and colleagues studied 348 elderly cancer patients (median age, 77.45 years) who had not had previous . Participants were evaluated at baseline using the abbreviated comprehensive geriatric assessment (aCGA), including the Mini-Mental State Exam, Timed Get Up and Go (GUG), Activities of Daily Living (ADL), in Daily Living (IADL), Mini Nutritional Assessment (MNA), Geriatric Depression Scale (GDS15), and comorbidities index (Cumulative Index Rating Scale-Geriatric).

The researchers found that 18.1 percent of participants had abnormal aCGA scores on the ADL, as did 73.0 percent on the IADL, 24.1 percent on the GUG, 19.0 percent on the MMS, 44.0 percent on the GDS15, and 64.9 percent on the MNA. Higher risk of early death was associated with advanced disease (odds ratio [OR], 3.9), a low MNA score (OR, 2.77), male gender (OR, 2.40), and long GUG (OR, 2.55).

"We recommend that the MNA and GUG, performed by a trained nurse, be maintained as part of routine pretreatment work-up in these patients to identify at-risk patients and to inform the decision-making process for chemotherapy," the authors write.

Several authors disclosed with pharmaceutical companies, many of which funded the study.

Explore further: Complementary meds used by 17 percent of elderly with cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Complementary meds used by 17 percent of elderly with cancer

March 2, 2012
(HealthDay) -- The prevalence of older people with cancer using complementary medications as they start a chemotherapy regimen is 17 percent, and is associated with less advanced disease and higher functional status, according ...

Financial hardship common among colon cancer patients

March 13, 2012
(HealthDay) -- Nearly 40 percent of patients undergoing adjuvant chemotherapy for stage III colon cancer experience financial hardship, even if they have health insurance coverage, according to research published online March ...

DNA repair pathway score for predicting chemotherapy response in ovarian cancer patients

April 13, 2012
A DNA repair pathway-focused score has the potential to help determine if first-line platinum based chemotherapy can benefit advanced-stage ovarian cancer patients, according to a study published April 13 in the Journal of ...

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.